Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

aTYR PHARMA (ATYR) Other Operating Expenses (2024 - 2025)

aTYR PHARMA (ATYR) has disclosed Other Operating Expenses for 3 consecutive years, with $62.8 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Other Operating Expenses rose 420.66% year-over-year to $62.8 million, compared with a TTM value of -$13.7 million through Dec 2025, up 51.09%, and an annual FY2025 reading of -$13.7 million, up 83.55% over the prior year.
  • Other Operating Expenses was $62.8 million for Q4 2025 at aTYR PHARMA, up from -$31.8 million in the prior quarter.
  • Across five years, Other Operating Expenses topped out at $62.8 million in Q4 2025 and bottomed at -$59.8 million in Q4 2023.
  • Average Other Operating Expenses over 3 years is -$11.3 million, with a median of -$19.7 million recorded in 2025.
  • Peak annual rise in Other Operating Expenses hit 420.66% in 2025, while the deepest fall reached 1036.5% in 2025.
  • Year by year, Other Operating Expenses stood at -$59.8 million in 2023, then skyrocketed by 67.22% to -$19.6 million in 2024, then surged by 420.66% to $62.8 million in 2025.
  • Business Quant data shows Other Operating Expenses for ATYR at $62.8 million in Q4 2025, -$31.8 million in Q3 2025, and -$25.0 million in Q2 2025.